Search clinical trials for: Irbesartan/hydrochlorothiazide

Total 502 results

Sanofi

Completed

Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension (COSIMA2)

Hypertension

India, Malaysia, Philippines, Singapore, Taiwan, Tunisia, Egypt, Korea, Republic of, Hong Kong, Indonesia, Morocco, Pakistan, Thailand, Vietnam
Damanhour University

Completed

Drug Interaction Between Irbesartan and Hydrochlorothiazide

Healthy

Egypt
Sanofi

Completed

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Hypertension

China
Sanofi
Bristol-Myers Squibb

Completed

AMISH : Aprovel for Management of Isolated Systolic Hypertension

Hypertension

Korea, Republic of, Mexico, Taiwan, Thailand, Philippines, Chile, China, Indonesia
Sanofi

Completed

Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing

Hypertension

Taiwan
Sanofi

Completed

Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension

Hypertension

Taiwan
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Hypertension

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

Hypertension

United States
Sanofi

Completed

ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination (ACTUAL)

Hypertension

Brazil, Tunisia, Argentina, Egypt, Mexico, Peru, Morocco, Colombia, Guatemala, Venezuela, Lebanon, Algeria, Ecuador, Panama, Saudi Arabia, United Arab Emirates
Sanofi

Completed

Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

Hypertension

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

Hypertension

United States, Canada, Germany, Russian Federation, France
Assistance Publique - Hôpitaux de Paris

Completed

PHARES Study: Management of Resistant Hypertension

Hypertension

France
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Therapeutic Equivalency

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Hypertension

United States, Belgium, Canada, Germany, Russian Federation, France, Israel, Netherlands
Sanofi

Completed

Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

Hypertension

Russian Federation
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Hypertension | Metabolic Syndrome

Spain, Italy, Russian Federation, Norway, France, Germany
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
Zhi-Hong Liu, M.D.

Terminated

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Obesity and Glomerulopathy

China
Steno Diabetes Center Copenhagen
Bristol-Myers Squibb; Sanofi-Synthelabo

Completed

Irbesartan in Type 2 Diabetes

Hypertension | Type 2 Diabetes | Microalbuminuria
Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
University of Southern Denmark
Bristol-Myers Squibb

Completed

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Myocardial Infarction

Denmark
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Diabetic Kidney Disease

China
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Sanofi
Bristol-Myers Squibb

Completed

I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

Hypertension

Egypt
Sanofi
Bristol-Myers Squibb

Completed

I PREVENT - Irbesartan In Hypertensive Diabetic Patients

Hypertension

Egypt
Sanofi
Bristol-Myers Squibb

Completed

I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Hypertension

Egypt
Ligand Pharmaceuticals

Completed

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Hypertension

United States
Insel Gruppe AG, University Hospital Bern

Completed

Hydrochlorothiazide for Kidney Stone Recurrence Prevention (NOSTONE)

Nephrolithiasis

Switzerland
Novartis

Completed

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Hypertension

Switzerland, Germany
Travere Therapeutics, Inc.

Active, not recruiting

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Focal Segmental Glomerulosclerosis

United States, Australia, Belgium, Croatia, Estonia, Germany, Hong Kong, Italy, Korea, Republic of, Poland, Portugal, Spain, Taiwan, United Kingdom, Argentina, Brazil, Canada, Czechia, Denmark, France, New Zealand, Sweden
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg

Healthy

United States
Hospital Infantil de Mexico Federico Gomez

Unknown

Comparison of the Impact of Diet vs Thiazide in BMD in Children With Idiopathic Hypercalciuria (HIC)

Nephrolithiasis | Hypercalciuria; Idiopathic

Mexico
Sanofi

Completed

Irbesartan and Amlodipine Combination in Controlling Blood Pressure (I-COMBO)

Hypertension

India, Philippines, Taiwan, Korea, Republic of
University of Magdeburg
Sanofi

Unknown

Irbesartan and Adhesion Molecules in AF (CREATIVE-AF)

Persistent Atrial Fibrillation

Germany
Sanofi

Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy (I-ADD)

Hypertension

Morocco, Brazil, Colombia, Guatemala, Mexico, Tunisia, United Arab Emirates, Venezuela
Assistance Publique - Hôpitaux de Paris

Recruiting

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (START-or-NOT)

Acute Kidney Injury

France
Handok Inc.

Completed

Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Sanofi

Completed

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Type 2 Diabetes Mellitus

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemia

Korea, Republic of
Alnylam Pharmaceuticals

Completed

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Hypertension

United Kingdom
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Medical Centre Leeuwarden

Completed

Hydrochloorthiazide and Hypernatriaemie

Hypernatraemia

Netherlands
Montefiore Medical Center
NCM USA

Completed

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Neuroendocrine Tumors
Università degli Studi dell'Insubria

Unknown

Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan

Diastolic Function | Left Atrial Volume | Renin Angiotensin System | Hypertensive Heart Disease | Antihypertensive Drugs

Italy
Daiichi Sankyo, Inc.

Completed

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Essential Hypertension

France, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy

Search clinical trials for: Irbesartan/hydrochlorothiazide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations